Skip to main content
Equibles
AVIR logo

AVIR · Atea Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track AVIR — free

Use AVIR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AVIR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.09 -0.04 (-0.78%)
Russell 2000 member Rebalance outlook locked
Market Cap
$415.46M
Shares
80.20M
Volume · Oct 5 93.95K Avg daily vol (3M) 305.18K

Atea Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Atea Pharmaceuticals, Inc. (AVIR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Conference
Investor event
2026-09-15
Atea Pharmaceuticals, Inc. (AVIR) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call
Diluted EPS
$-0.41
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Confident tone Phase 3 HCV pivotal trials Hepatitis E (HEV) program / AT587 Regulatory engagement
Diluted EPS
$-0.57
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Confident tone Commercial launch preparation Hepatitis C market opportunity Phase 3 HCV program execution
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript
Confident tone Bemifovir and riluzole regimen differentiation Phase III CBEYOND and C FORWARD trials Phase II SVR12 history and predictability
Diluted EPS
$-0.53
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript
Confident tone Unmet Need and Market Opportunity HCV Phase III Program Progress Market Research / Prescriber Preference
Diluted EPS
$-0.44
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-14
Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript
Confident tone Phase 3 trial design and initiation HCV market opportunity and unmet need Phase 2 results and HCV cure rate
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
Positive tone HCV Phase III readiness HCV unmet need and patient profile FDA end of Phase II meeting
Diluted EPS
$-0.37
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
Confident tone COVID-19 program (bemnifosbuvir / SUNRISE-3) HCV combination program (bemnifosbuvir + ruzasvir) Phase 2 HCV leading cohort results (EASL)
Diluted EPS
$-0.48
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
Confident tone HCV Phase II / Phase III program Fixed-dose combination tablet development COVID-19 / bemnifosbuvir program
Diluted EPS
$-0.75
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
Confident tone HCV Phase 2 combination COVID-19 / SUNRISE-3 Phase 3 Regulatory pathway / Phase 3 design
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.40
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Atea Pharmaceuticals, Inc. (AVIR) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.34
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.43
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Atea Pharmaceuticals, Inc. (AVIR) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.10
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Atea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.38
▼ 2000% YoY
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Atea Pharmaceuticals, Inc. (AVIR) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.51
▼ 250% YoY
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript
Revenue
$192.18M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Atea Pharmaceuticals, Inc. (AVIR) Q3 2021 Earnings Call Transcript
Revenue
$32.81M
Diluted EPS
$-0.34
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Atea Pharmaceuticals, Inc. (AVIR) Q2 2021 Earnings Call Transcript
Revenue
$60.39M
Diluted EPS
$0.02
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Atea Pharmaceuticals, Inc. (AVIR) Q1 2021 Earnings Call Transcript
Revenue
$65.98M
Diluted EPS
$0.34
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 webcasts
Key facts CIK 1593899 CUSIP 04683R106 13F (30d) 3 filings 3 filers Visit website Investor relations